Photodynamic therapy in gynaecologic cancer.
We started photodynamic therapy in gynaecologic tumors in 1988. Seven patients with endometrial carcinomas stage FIGO 1a (restricted to the endometrium) were treated primarily and also 4 patients with recurrences of vaginal and vault cervix carcinoma, carcinoma of the corpus uteri and the vulva. Residual tumors after conventional therapy of cervix and vulvar carcinoma were treated in 2 patients. Tumor illumination was performed by an Argon dye laser 24-72 h following the intravenous administration of haematoporphyrin derivatives (HPD) (Photosan III, 2 mg kg-1 body weight). The intracavitary tumor irradiation by means of a glass fibre was controlled by ultrasound. Superficial and small lesions of vaginal and vulvar carcinomas were subjected to superficial light irradiation; whereas tumors exceeding 1 cm in depth were treated interstitially. Tumor response was estimated 1 month after therapy. Complete remission was achieved in 8 patients, partial remission in 2, and no remission in 3 cases. Subsequent radiotherapy was performed in 3 patients with bleeding endometrial cancer with consecutive complete response.
Koren
H
H
Special Department of Radiotherapy, City Hospital, Lainz, Austria.
Alth
G
G
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006415:Hematoporphyrins; D006801:Humans; D007834:Lasers; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy; D014625:Vaginal Neoplasms / Q000188:drug therapy; D014846:Vulvar Neoplasms / Q000188:drug therapy
D006415:Hematoporphyrins; D017319:Photosensitizing Agents; C071875:photosan III